Literature DB >> 22223732

Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men.

S Goya Wannamethee1, Peter H Whincup, A Gerald Shaper, Lucy Lennon, Naveed Sattar.   

Abstract

OBJECTIVE: The relationship between γ-glutamyl transferase (GGT) and heart failure (HF) in older adults is unknown. We have examined the relationship between GGT, other markers of hepatic function (alanine aminotransferase, aspartate transaminase, and alkaline phosphatase), and incident HF in older men. METHODS AND
RESULTS: This was a prospective study of 3494 men aged 60 to 79 years with no diagnosed HF or myocardial infarction followed up for a mean period of 9 years, in whom there were 168 incident HF cases. Elevated GGT (top quartile, ≥38 U/L) was associated with significantly increased risk of incident HF in men aged<70 years but not in men aged≥70 years (test for age-GGT interaction, P<0.0001). The increased risk of HF associated with elevated GGT persisted after adjustment for a wide range of established and novel risk factors for HF, including diabetes, stroke, obesity, systolic blood pressure, atrial fibrillation, lung function, inflammation (C-reactive protein), endothelial dysfunction (von Willebrand factor), leptin, and N terminal pro brain natriuretic peptide (adjusted hazard ratio [95% CI], 1.91 [1.07, 3.42]). Other liver function markers showed no significant associations with HF after similar adjustments.
CONCLUSION: Elevated GGT was associated with increased risk of HF in men aged<70 years. Additional studies are now needed to determine the mechanisms responsible.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223732     DOI: 10.1161/ATVBAHA.111.240457

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  21 in total

1.  Increased serum gamma-glutamyltransferase levels are associated with ventricular instability in type 2 diabetes.

Authors:  Kun Wang; Ling Li; Yang Wu; Yu Yang; Jie Chen; Danyu Zhang; Zhoujun Liu; Juan Xu; Meng Cao; Xiaodong Mao; Chao Liu
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 2.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

Review 3.  The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Authors:  Sven M Francque
Journal:  Eur Cardiol       Date:  2014-07

Review 4.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 5.  Role of gamma-glutamyltransferase in cardiovascular diseases.

Authors:  Shengyang Jiang; Donglin Jiang; Yijia Tao
Journal:  Exp Clin Cardiol       Date:  2013

Review 6.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

7.  Prevalence of heart failure signs and symptoms in a large primary care population identified through the use of text and data mining of the electronic health record.

Authors:  Rajakrishnan Vijayakrishnan; Steven R Steinhubl; Kenney Ng; Jimeng Sun; Roy J Byrd; Zahra Daar; Brent A Williams; Christopher deFilippi; Shahram Ebadollahi; Walter F Stewart
Journal:  J Card Fail       Date:  2014-04-04       Impact factor: 5.712

8.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Mary E Rinella
Journal:  Curr Hepatol Rep       Date:  2016-03-28

9.  Associations between total serum GGT activity and metabolic risk: MESA.

Authors:  Ryan Bradley; Annette L Fitzpatrick; Nancy S Jenny; Duk-Hee Lee; David R Jacobs
Journal:  Biomark Med       Date:  2013-10       Impact factor: 2.851

10.  The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study.

Authors:  Laura S Chiu; Alison Pedley; Joseph M Massaro; Emelia J Benjamin; Gary F Mitchell; David D McManus; Jayashri Aragam; Ramachandran S Vasan; Susan Cheng; Michelle T Long
Journal:  Liver Int       Date:  2020-07-25       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.